QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross‐sectional analysis of the randomized AGMT 02 study

• Published in: EJHaem Vol. 5; no. 3; pp. 494 - 504
• Main Authors: Ludwig, Heinz, Melchardt, Thomas, Schweitzer, Ilvy, Sormann, Siegfried, Schreder, Martin, Andel, Johannes, Hartmann, Bernd, Zojer, Niklas, Schöffmann, Laurenz, Gunsilius, Eberhard, Podar, Klaus, Egle, Alexander, Willenbacher, Wolfgang, Wöll, Ewald, Ruckser, Reinhard, Bozic, Boris, Krauth, Maria‐Theresa, Petzer, Andreas, Schmitt, Clemens, Machherndl‐Spandl, Sigrid, Agis, Hermine, Fillitz, Michael, Wang, Song‐Yau, Knop, Stefan, Greil, Richard
• Format: Journal Article
• Language: English
• Published: Hoboken John Wiley & Sons, Inc 01.06.2024; John Wiley and Sons Inc; Wiley
• Subjects: carfilzomib; Compliance; Cytogenetics; Haematologic Malignancy ‐ Plasma Cell; Induction therapy; Insomnia; lenalidomide; Medical treatment; Multiple myeloma; Neuropathy; Pain; Patients; Public health; Quality of life; Questionnaires; Sleep disorders; Statistical analysis; thalidomide
• ISSN: 2688-6146; 2688-6146
• DOI: 10.1002/jha2.925

Understanding the impact of induction and maintenance therapy on patients’ quality of life (QoL) is important for treatment selection. This study aims to compare patient‐reported QoL between patients treated with KTd or KRd induction therapy and K maintenance therapy or observation. QoL was assessed using the EORTC QOL‐C 30 and QOL‐MY20 questionnaires in the AGMT‐02 study, in which 123 patients with newly diagnosed transplant ineligible multiple myeloma were randomized to nine cycles of either KTd or KRd induction therapy, followed by 12 cycles of K maintenance therapy, or observation. Longitudinal assessments showed statistically significant improvements in global health‐related QoL, various disease symptoms and pain for both treatment regimens. KTd improved insomnia and fatigue, and KRd improved physical functioning. Cross‐sectional comparisons indicated a “slight” superiority of KTd over KRd in several scales, with the exception of higher neuropathy scores with KTd. During maintenance, longitudinal comparisons showed no statistically significant changes. Cross‐sectional comparisons revealed a “slight” improvement in cognitive functioning during carfilzomib therapy, but a worsening in most other QoL scales. Induction therapy led to improvements in most QoL items, while maintenance therapy with K maintenance was associated with “slight” or “moderate” impairments in several QoL scales compared with the observation group.